Engineered immune cells take on tough Muscle-Weakening disease

NCT ID NCT06704269

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new treatment called YTB323 for people with generalized myasthenia gravis that hasn't responded to standard therapies. YTB323 is a CAR-T cell therapy, meaning a patient's own immune cells are modified in a lab to better attack the disease. The study will enroll 15 participants to check safety, how long the cells last in the body, and whether they improve muscle weakness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: YTB323 (a CAR-T cell therapy given by infusion)
What this could lead to: If successful, this could point toward a new treatment option for people with hard-to-control myasthenia gravis, potentially reducing symptoms and reliance on other medications.
What could go wrong: This is an early-phase trial with only 15 participants, so results may not apply to everyone. CAR-T therapies can cause serious side effects like cytokine release syndrome and nerve problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENERALIZED MYASTHENIA GRAVIS

Contacts and locations

Locations

Houston Methodist Hospital
RECRUITING

Houston, Texas, 77030, United States
Novartis Investigative Site
RECRUITING

Bordeaux, 33076, France
Novartis Investigative Site
RECRUITING

Brest, 29200, France
Novartis Investigative Site
RECRUITING

Lille, 59037, France
Novartis Investigative Site
RECRUITING

Chiba, Chiba, 2608677, Japan
Novartis Investigative Site
RECRUITING

Kyoto, 6068507, Japan
Novartis Investigative Site
RECRUITING

Sheffield, South Yorkshire, S10 2JF, United Kingdom
Novartis Investigative Site
RECRUITING

London, SE5 9RS, United Kingdom
Thomas Jefferson University
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
Univ Cali Irvine ALS Neuromuscular
RECRUITING

Orange, California, 92868, United States
Wake Forest Univ School of Medicine
RECRUITING

Winston-Salem, North Carolina, 27157-1052, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.